Consensus $2.92. Raises FY23 revenue view to up 15%-17% from up 12%-15%, consensus $1.14B. Sees FY23 adjusted operating margin 18%-19%. Sees FY23 free cash flow $160M-$180M.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HAE:
- Haemonetics 3rd Quarter Fiscal Year 2023 Earnings Release Available on Investor Relations Website
- Haemonetics price target raised to $110 from $100 at Mizuho
- ViewRay CFO to step down, William Burke to succeed
- Haemonetics management to meet virtually with JMP Securities
- Haemonetics management to meet with Mizuho
